![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: EGR2 |
Gene summary for EGR2 |
![]() |
Gene information | Species | Human | Gene symbol | EGR2 | Gene ID | 1959 |
Gene name | early growth response 2 | |
Gene Alias | AT591 | |
Cytomap | 10q21.3 | |
Gene Type | protein-coding | GO ID | GO:0000902 | UniProtAcc | P11161 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
1959 | EGR2 | LZE4T | Human | Esophagus | ESCC | 2.21e-04 | 6.41e-01 | 0.0811 |
1959 | EGR2 | LZE8T | Human | Esophagus | ESCC | 3.14e-09 | 7.59e-01 | 0.067 |
1959 | EGR2 | LZE21D1 | Human | Esophagus | HGIN | 2.73e-03 | 1.32e-02 | 0.0632 |
1959 | EGR2 | LZE24T | Human | Esophagus | ESCC | 1.93e-05 | 8.88e-01 | 0.0596 |
1959 | EGR2 | LZE21T | Human | Esophagus | ESCC | 2.03e-04 | 6.54e-01 | 0.0655 |
1959 | EGR2 | P2T-E | Human | Esophagus | ESCC | 2.00e-46 | 1.16e+00 | 0.1177 |
1959 | EGR2 | P4T-E | Human | Esophagus | ESCC | 1.92e-15 | 4.29e-01 | 0.1323 |
1959 | EGR2 | P5T-E | Human | Esophagus | ESCC | 1.49e-22 | 9.15e-01 | 0.1327 |
1959 | EGR2 | P8T-E | Human | Esophagus | ESCC | 2.49e-18 | 6.49e-01 | 0.0889 |
1959 | EGR2 | P9T-E | Human | Esophagus | ESCC | 1.50e-05 | 1.98e-01 | 0.1131 |
1959 | EGR2 | P10T-E | Human | Esophagus | ESCC | 2.89e-09 | 1.23e-01 | 0.116 |
1959 | EGR2 | P11T-E | Human | Esophagus | ESCC | 1.40e-05 | 2.87e-01 | 0.1426 |
1959 | EGR2 | P12T-E | Human | Esophagus | ESCC | 6.36e-06 | 3.67e-01 | 0.1122 |
1959 | EGR2 | P15T-E | Human | Esophagus | ESCC | 5.87e-18 | 8.17e-01 | 0.1149 |
1959 | EGR2 | P16T-E | Human | Esophagus | ESCC | 1.23e-28 | 1.12e+00 | 0.1153 |
1959 | EGR2 | P20T-E | Human | Esophagus | ESCC | 1.04e-14 | 1.34e+00 | 0.1124 |
1959 | EGR2 | P22T-E | Human | Esophagus | ESCC | 6.01e-07 | 5.74e-01 | 0.1236 |
1959 | EGR2 | P23T-E | Human | Esophagus | ESCC | 1.62e-05 | 8.30e-01 | 0.108 |
1959 | EGR2 | P26T-E | Human | Esophagus | ESCC | 2.87e-53 | 1.24e+00 | 0.1276 |
1959 | EGR2 | P27T-E | Human | Esophagus | ESCC | 1.46e-23 | 1.04e+00 | 0.1055 |
Page: 1 2 3 4 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:000691317 | Oral cavity | OSCC | nucleocytoplasmic transport | 204/7305 | 301/18723 | 2.65e-24 | 6.98e-22 | 204 |
GO:005116917 | Oral cavity | OSCC | nuclear transport | 204/7305 | 301/18723 | 2.65e-24 | 6.98e-22 | 204 |
GO:005116817 | Oral cavity | OSCC | nuclear export | 112/7305 | 154/18723 | 1.70e-17 | 1.56e-15 | 112 |
GO:00182056 | Oral cavity | OSCC | peptidyl-lysine modification | 216/7305 | 376/18723 | 2.32e-13 | 1.16e-11 | 216 |
GO:00066119 | Oral cavity | OSCC | protein export from nucleus | 42/7305 | 57/18723 | 1.10e-07 | 1.87e-06 | 42 |
GO:00107209 | Oral cavity | OSCC | positive regulation of cell development | 159/7305 | 298/18723 | 3.06e-07 | 4.66e-06 | 159 |
GO:004851116 | Oral cavity | OSCC | rhythmic process | 157/7305 | 298/18723 | 1.00e-06 | 1.36e-05 | 157 |
GO:004343419 | Oral cavity | OSCC | response to peptide hormone | 208/7305 | 414/18723 | 1.83e-06 | 2.35e-05 | 208 |
GO:000150310 | Oral cavity | OSCC | ossification | 203/7305 | 408/18723 | 5.54e-06 | 6.19e-05 | 203 |
GO:003286816 | Oral cavity | OSCC | response to insulin | 138/7305 | 264/18723 | 7.54e-06 | 8.15e-05 | 138 |
GO:00507696 | Oral cavity | OSCC | positive regulation of neurogenesis | 120/7305 | 225/18723 | 8.45e-06 | 9.02e-05 | 120 |
GO:00420635 | Oral cavity | OSCC | gliogenesis | 154/7305 | 301/18723 | 1.10e-05 | 1.14e-04 | 154 |
GO:00454448 | Oral cavity | OSCC | fat cell differentiation | 120/7305 | 229/18723 | 2.48e-05 | 2.32e-04 | 120 |
GO:00507679 | Oral cavity | OSCC | regulation of neurogenesis | 179/7305 | 364/18723 | 4.49e-05 | 3.84e-04 | 179 |
GO:00519624 | Oral cavity | OSCC | positive regulation of nervous system development | 135/7305 | 272/18723 | 2.20e-04 | 1.44e-03 | 135 |
GO:00169253 | Oral cavity | OSCC | protein sumoylation | 33/7305 | 53/18723 | 5.11e-04 | 2.98e-03 | 33 |
GO:00072723 | Oral cavity | OSCC | ensheathment of neurons | 72/7305 | 136/18723 | 6.59e-04 | 3.70e-03 | 72 |
GO:00083663 | Oral cavity | OSCC | axon ensheathment | 72/7305 | 136/18723 | 6.59e-04 | 3.70e-03 | 72 |
GO:00425523 | Oral cavity | OSCC | myelination | 71/7305 | 134/18723 | 6.93e-04 | 3.86e-03 | 71 |
GO:0014015 | Oral cavity | OSCC | positive regulation of gliogenesis | 39/7305 | 66/18723 | 7.46e-04 | 4.07e-03 | 39 |
Page: 1 2 3 4 5 6 7 8 9 10 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa052039 | Esophagus | HGIN | Viral carcinogenesis | 53/1383 | 204/8465 | 2.58e-04 | 2.71e-03 | 2.15e-03 | 53 |
hsa0516639 | Esophagus | HGIN | Human T-cell leukemia virus 1 infection | 51/1383 | 222/8465 | 5.84e-03 | 4.05e-02 | 3.22e-02 | 51 |
hsa0520315 | Esophagus | HGIN | Viral carcinogenesis | 53/1383 | 204/8465 | 2.58e-04 | 2.71e-03 | 2.15e-03 | 53 |
hsa05166114 | Esophagus | HGIN | Human T-cell leukemia virus 1 infection | 51/1383 | 222/8465 | 5.84e-03 | 4.05e-02 | 3.22e-02 | 51 |
hsa05166211 | Esophagus | ESCC | Human T-cell leukemia virus 1 infection | 164/4205 | 222/8465 | 8.13e-14 | 2.09e-12 | 1.07e-12 | 164 |
hsa0520325 | Esophagus | ESCC | Viral carcinogenesis | 137/4205 | 204/8465 | 2.47e-07 | 1.88e-06 | 9.62e-07 | 137 |
hsa051619 | Esophagus | ESCC | Hepatitis B | 108/4205 | 162/8465 | 7.68e-06 | 4.15e-05 | 2.12e-05 | 108 |
hsa046259 | Esophagus | ESCC | C-type lectin receptor signaling pathway | 73/4205 | 104/8465 | 1.57e-05 | 7.98e-05 | 4.09e-05 | 73 |
hsa05166310 | Esophagus | ESCC | Human T-cell leukemia virus 1 infection | 164/4205 | 222/8465 | 8.13e-14 | 2.09e-12 | 1.07e-12 | 164 |
hsa0520335 | Esophagus | ESCC | Viral carcinogenesis | 137/4205 | 204/8465 | 2.47e-07 | 1.88e-06 | 9.62e-07 | 137 |
hsa0516114 | Esophagus | ESCC | Hepatitis B | 108/4205 | 162/8465 | 7.68e-06 | 4.15e-05 | 2.12e-05 | 108 |
hsa0462513 | Esophagus | ESCC | C-type lectin receptor signaling pathway | 73/4205 | 104/8465 | 1.57e-05 | 7.98e-05 | 4.09e-05 | 73 |
hsa046258 | Oral cavity | OSCC | C-type lectin receptor signaling pathway | 73/3704 | 104/8465 | 3.83e-08 | 3.12e-07 | 1.59e-07 | 73 |
hsa051618 | Oral cavity | OSCC | Hepatitis B | 103/3704 | 162/8465 | 2.34e-07 | 1.51e-06 | 7.69e-07 | 103 |
hsa052038 | Oral cavity | OSCC | Viral carcinogenesis | 124/3704 | 204/8465 | 5.57e-07 | 3.28e-06 | 1.67e-06 | 124 |
hsa0462512 | Oral cavity | OSCC | C-type lectin receptor signaling pathway | 73/3704 | 104/8465 | 3.83e-08 | 3.12e-07 | 1.59e-07 | 73 |
hsa0516113 | Oral cavity | OSCC | Hepatitis B | 103/3704 | 162/8465 | 2.34e-07 | 1.51e-06 | 7.69e-07 | 103 |
hsa0520314 | Oral cavity | OSCC | Viral carcinogenesis | 124/3704 | 204/8465 | 5.57e-07 | 3.28e-06 | 1.67e-06 | 124 |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
EGR2 | SNV | Missense_Mutation | c.1214N>A | p.Arg405Gln | p.R405Q | P11161 | protein_coding | deleterious(0) | probably_damaging(0.995) | TCGA-A2-A04W-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD | |
EGR2 | SNV | Missense_Mutation | novel | c.367N>T | p.Gly123Trp | p.G123W | P11161 | protein_coding | deleterious(0.04) | probably_damaging(0.933) | TCGA-C8-A8HQ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
EGR2 | SNV | Missense_Mutation | c.1273G>A | p.Glu425Lys | p.E425K | P11161 | protein_coding | deleterious(0.01) | possibly_damaging(0.677) | TCGA-D8-A1JN-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Hormone Therapy | anastrozolum | SD | |
EGR2 | SNV | Missense_Mutation | novel | c.899C>A | p.Ala300Glu | p.A300E | P11161 | protein_coding | tolerated(0.47) | benign(0.137) | TCGA-HN-A2NL-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | SD |
EGR2 | insertion | Nonsense_Mutation | novel | c.252_253insTCTGTAAAATGAAGATACTTATTTTTCAGGGTTGTAAGAGTA | p.Ala84_Pro85insSerValLysTerArgTyrLeuPhePheArgValValArgVal | p.A84_P85insSVK*RYLFFRVVRV | P11161 | protein_coding | TCGA-AO-A03V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | fluorouracil | SD | ||
EGR2 | deletion | Frame_Shift_Del | c.1337delG | p.Gly446AlafsTer89 | p.G446Afs*89 | P11161 | protein_coding | TCGA-D8-A27V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD | |||
EGR2 | SNV | Missense_Mutation | novel | c.655C>T | p.Leu219Phe | p.L219F | P11161 | protein_coding | deleterious(0.02) | possibly_damaging(0.799) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
EGR2 | SNV | Missense_Mutation | novel | c.188N>G | p.Asp63Gly | p.D63G | P11161 | protein_coding | tolerated(0.8) | benign(0.003) | TCGA-A6-5661-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
EGR2 | SNV | Missense_Mutation | c.1085N>A | p.Arg362Gln | p.R362Q | P11161 | protein_coding | deleterious(0) | probably_damaging(0.995) | TCGA-A6-6141-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | 5-fu | SD | |
EGR2 | SNV | Missense_Mutation | c.1130G>A | p.Arg377His | p.R377H | P11161 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-AA-3672-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
Page: 1 2 3 4 5 6 7 8 9 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
1959 | EGR2 | TRANSCRIPTION FACTOR | RETINOIC ACID | 1361214 |
Page: 1 |